MiNK Therapeutics, Inc.
INKT
$10.72
$0.212.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.51% | -0.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -394.53% | -- | |||
| Total Operating Expenses | -15.02% | -13.68% | |||
| Operating Income | 15.02% | 13.68% | |||
| Income Before Tax | 9.89% | 31.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.89% | 31.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.89% | 31.86% | |||
| EBIT | 15.02% | 13.68% | |||
| EBITDA | 15.06% | 13.73% | |||
| EPS Basic | 14.57% | 38.93% | |||
| Normalized Basic EPS | 14.57% | 33.19% | |||
| EPS Diluted | 14.57% | 38.93% | |||
| Normalized Diluted EPS | 14.57% | 33.19% | |||
| Average Basic Shares Outstanding | 5.47% | 11.58% | |||
| Average Diluted Shares Outstanding | 5.47% | 11.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||